Envisioning a new future for patients with inherited retinal diseases

Groundbreaking gene therapy

 

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases (IRDs) and other retinal and refractive disorders.

Patient-Guided
Patient-Guided
Gene Therapy Pipeline
Gene Therapy Pipeline
Unique Approach
Unique Approach

Preserving vision

Targeting mutations in genes causing inherited retinal diseases

Opus Genetics’ focus is on developing and advancing treatments to address mutations in genes that cause loss of vision, including bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP), while building out an engine to efficiently solve for many other inherited blinding conditions. Read more about our approach.

Human eye with blowup showing the detail of the structure of the retina

“I’ve dedicated my career to the research and development of treatments for blinding diseases, and I’m eager to continue to build on this work with Opus.”

—Dr. Jean Bennett, Scientific Advisor

Jean Bennett

"Hope is what we received when we heard about the potential treatment for Braydon’s rare inherited retinal disease. We are very excited that Opus’ focus is on helping people with rare eye diseases!"